Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia.

Jena AB, Sun E, Goldman DP.

J Gen Intern Med. 2013 Feb;28(2):223-30. doi: 10.1007/s11606-012-2211-5. Epub 2012 Sep 7.

2.

Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.

Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV.

Clin Infect Dis. 2012 Jan 1;54(1):33-42. doi: 10.1093/cid/cir767. Epub 2011 Nov 18.

3.

Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia.

de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk-Lafeber AB, Siersema PD, Kusters GC, Laheij RJ.

Aliment Pharmacol Ther. 2012 Nov;36(10):941-9. doi: 10.1111/apt.12069. Epub 2012 Oct 3.

4.

Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis.

Giuliano C, Wilhelm SM, Kale-Pradhan PB.

Expert Rev Clin Pharmacol. 2012 May;5(3):337-44. doi: 10.1586/ecp.12.20.

PMID:
22697595
5.

Proton-pump inhibitor use and the risk for community-acquired pneumonia.

Sarkar M, Hennessy S, Yang YX.

Ann Intern Med. 2008 Sep 16;149(6):391-8.

PMID:
18794558
6.

Pharmacotherapy and the risk for community-acquired pneumonia.

Gau JT, Acharya U, Khan S, Heh V, Mody L, Kao TC.

BMC Geriatr. 2010 Jul 6;10:45. doi: 10.1186/1471-2318-10-45.

7.

Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs.

Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR.

Am J Med. 2010 Jan;123(1):47-53. doi: 10.1016/j.amjmed.2009.05.032.

PMID:
20102991
8.

Sources of heterogeneity in case-control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia.

de Groot MC, Klungel OH, Leufkens HG, van Dijk L, Grobbee DE, van de Garde EM.

Eur J Epidemiol. 2014 Oct;29(10):767-75. doi: 10.1007/s10654-014-9941-0. Epub 2014 Aug 26.

PMID:
25154551
9.

Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis.

Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA.

PLoS One. 2015 Jun 4;10(6):e0128004. doi: 10.1371/journal.pone.0128004. eCollection 2015. Review.

10.

Microbial evaluation of proton-pump inhibitors and the risk of pneumonia.

Meijvis SC, Cornips MC, Voorn GP, Souverein PC, Endeman H, Biesma DH, Leufkens HG, van de Garde EM.

Eur Respir J. 2011 Nov;38(5):1165-72. doi: 10.1183/09031936.00020811. Epub 2011 Apr 8.

11.

Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK.

Suh DC, Hunsche E, Shin HC, Mavros P.

Rheumatology (Oxford). 2008 Apr;47(4):458-63. doi: 10.1093/rheumatology/kem375. Epub 2008 Feb 7.

12.

Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study.

Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA.

Pharmacoepidemiol Drug Saf. 2010 Aug;19(8):792-802. doi: 10.1002/pds.1978.

13.

Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands.

van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD.

Aliment Pharmacol Ther. 2009 Mar 1;29(5):571-9. doi: 10.1111/j.1365-2036.2008.03900.x. Epub 2008 Nov 25.

14.

Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis.

Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, Teare GF, Ravani P, Ernst P, Dormuth CR; CNODES Investigators.

Gut. 2014 Apr;63(4):552-8. doi: 10.1136/gutjnl-2013-304738. Epub 2013 Jul 15.

15.

Factors associated with the initiation of proton pump inhibitors in corticosteroid users.

Munson JC, Wahl PM, Daniel G, Kimmel SE, Hennessy S.

Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):366-74. doi: 10.1002/pds.2350. Epub 2012 Jan 25.

16.

Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia.

Roughead EE, Ramsay EN, Pratt NL, Ryan P, Gilbert AL.

Med J Aust. 2009 Feb 2;190(3):114-6.

PMID:
19203305
17.

[Proton pump inhibitors: impact of professional practice evaluation on prescriptions pertinence].

Fuzier R, Maguès JP, Dupuis E, Pomiès S, Segui S, Sénard JM.

Ann Fr Anesth Reanim. 2011 Nov;30(11):814-8. doi: 10.1016/j.annfar.2011.07.004. Epub 2011 Oct 5. French.

PMID:
21981846
18.

Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.

Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME.

JAMA Intern Med. 2016 Feb;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193.

19.

Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.

Sarafoff N, Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne RA, Mehilli J, Schömig A, Kastrati A.

Thromb Haemost. 2010 Sep;104(3):626-32. doi: 10.1160/TH09-11-0800. Epub 2010 Jul 20.

PMID:
20664905
20.

Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study.

Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE.

Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):269-75. doi: 10.1002/pds.1715.

PMID:
19235776
Items per page

Supplemental Content

Write to the Help Desk